Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Somatostatin receptor imaging: predictive and prognostic considerations

L B Anthony1, W Martin, D Delbeke

  • 1Department of Medicine, Vanderbilt University, Nashville, Tenn., USA.

Digestion
|January 1, 1996
PubMed
Summary

The 111In-pentetreotide scan effectively identified metastatic disease in carcinoid patients, influencing treatment outcomes. Somatostatin receptor imaging is crucial for accurate diagnosis and assessing response to somatostatin analogue therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can an amino acid-based oral rehydration solution be effective in managing immune therapy-induced diarrhea?

Medical hypotheses·2019
Same author

TRACE AMINE DEFICIT IN DEPRESSIVE ILLNESS: THE PHENYLALANINE CONNEXION.

Acta psychiatrica Scandinavica·2017
Same author

Detoxified alcoholics, major depressives and tyramine sulphate excretion.

Journal of psychopharmacology (Oxford, England)·2012
Same author

The place of chemical pathology in the development of psychopharmacology.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Monoamine oxidase inhibitors in depression: history and mythology.

Journal of psychopharmacology (Oxford, England)·2012

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Endocrinology

Background:

  • Carcinoid syndrome and related neuroendocrine tumors present diagnostic challenges.
  • Standard diagnostic methods may underestimate somatostatin receptor expression.
  • Accurate staging and assessment of therapeutic response are critical for patient management.

Purpose of the Study:

  • To evaluate the diagnostic utility of 111In-pentetreotide scintigraphy in carcinoid patients.
  • To assess the correlation between somatostatin receptor expression and clinical response to somatostatin analogues.
  • To analyze the impact of somatostatin analogue therapy on survival in carcinoid syndrome.

Main Methods:

  • 111In-pentetreotide scintigraphy was performed on patients with carcinoid tumors and other neuroendocrine neoplasms.

Related Experiment Videos

  • Somatostatin receptor presence was assessed using scintigraphy and compared with hormonal response criteria.
  • Survival data of patients treated with somatostatin analogues were retrospectively reviewed.

    • Main Results:

    • 111In-pentetreotide scans identified additional metastatic sites in 12 carcinoid patients and influenced therapeutic outcomes in 36 patients.
    • Somatostatin receptors were detected in a high percentage of carcinoid and atypical carcinoid patients.
    • Patients with metastatic carcinoids showed significant 5-hydroxyindoleacetic acid (5-HIAA) suppression with octreotide therapy, indicating receptor positivity.
    • A substantial improvement in 5-year survival was observed in patients treated during the somatostatin analogue era compared to historical controls.

    Conclusions:

    • 111In-pentetreotide scintigraphy is a valuable tool for detecting metastatic disease and occult primaries in carcinoid patients.
    • Scintigraphy provides a more accurate assessment of somatostatin receptor status than standard hormonal criteria.
    • Somatostatin analogue therapy significantly improves survival in carcinoid syndrome patients.